Compare ORKA & STRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORKA | STRA |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 1996 |
| Metric | ORKA | STRA |
|---|---|---|
| Price | $57.54 | $77.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $92.50 | $87.00 |
| AVG Volume (30 Days) | ★ 1.5M | 230.1K |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.04% |
| EPS Growth | N/A | ★ 15.85 |
| EPS | N/A | ★ 1.48 |
| Revenue | N/A | ★ $997,137,000.00 |
| Revenue This Year | N/A | $4.71 |
| Revenue Next Year | N/A | $4.67 |
| P/E Ratio | ★ N/A | $52.20 |
| Revenue Growth | N/A | ★ 57.23 |
| 52 Week Low | $10.97 | $69.70 |
| 52 Week High | $91.00 | $92.98 |
| Indicator | ORKA | STRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 43.65 |
| Support Level | $54.99 | $76.28 |
| Resistance Level | $91.00 | $84.09 |
| Average True Range (ATR) | 3.14 | 2.10 |
| MACD | -0.95 | -0.13 |
| Stochastic Oscillator | 23.40 | 22.79 |
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.